A Study of TJ101 in People With Solid Tumor Cancer

Full Title

A Phase I, First in Human (FIH), Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients with Advanced/Metastatic Solid Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Jessica Ross’ office at 646-608-4422.